NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.
Publication
, Journal Article
Schaeffer, EM; Srinivas, S; Adra, N; An, Y; Barocas, D; Bitting, R; Bryce, A; Chapin, B; Cheng, HH; D'Amico, AV; Desai, N; Dorff, T; Gao, X ...
Published in: J Natl Compr Canc Netw
December 2022
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, recurrent, and metastatic disease. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. These NCCN Guidelines Insights summarizes much of the panel's discussions for the 4.2022 and 1.2023 updates to the guidelines regarding systemic therapy for metastatic prostate cancer.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
December 2022
Volume
20
Issue
12
Start / End Page
1288 / 1298
Location
United States
Related Subject Headings
- Risk Assessment
- Prostatic Neoplasms
- Oncology & Carcinogenesis
- Male
- Humans
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Barocas, D., Bitting, R., … Freedman-Cass, D. A. (2022). NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023. J Natl Compr Canc Netw, 20(12), 1288–1298. https://doi.org/10.6004/jnccn.2022.0063
Schaeffer, Edward M., Sandy Srinivas, Nabil Adra, Yi An, Daniel Barocas, Rhonda Bitting, Alan Bryce, et al. “NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.” J Natl Compr Canc Netw 20, no. 12 (December 2022): 1288–98. https://doi.org/10.6004/jnccn.2022.0063.
Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023. J Natl Compr Canc Netw. 2022 Dec;20(12):1288–98.
Schaeffer, Edward M., et al. “NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.” J Natl Compr Canc Netw, vol. 20, no. 12, Dec. 2022, pp. 1288–98. Pubmed, doi:10.6004/jnccn.2022.0063.
Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D’Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Berardi RA, Shead DA, Freedman-Cass DA. NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023. J Natl Compr Canc Netw. 2022 Dec;20(12):1288–1298.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
December 2022
Volume
20
Issue
12
Start / End Page
1288 / 1298
Location
United States
Related Subject Headings
- Risk Assessment
- Prostatic Neoplasms
- Oncology & Carcinogenesis
- Male
- Humans
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis